Functional characterization of a pore‐forming effector TseMt from the H4 type VI secretion system of Pseudomonas aeruginosa
mLife · 2026-08 · 5 (4) · 417-431
DOI: 10.1002/mlf2.70108 ↗Kurz gefasst
Fachartikel in der Zeitschrift mLife, online erschienen am 27.08.2026. Verfasst von Liwen Wu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Microbiology School of Life Sciences, Guangming Advanced Research Institute, Southern University of Science and Technolo…. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Pseudomonas aeruginosa is a major nosocomial pathogen in which the type VI secretion system (T6SS) contributes to interbacterial competition and virulence. While most strains encode three T6SSs, additional T6SS clusters have been identified in clinical isolates through comparative genomics, but their functions and effector biology remain undefined. Here, we identify TseMt as a major antibacterial effector associated with an H4‐T6SS in a clinical P. aeruginosa isolate LYSZa7. TseMt is a periplasmically active toxin whose activity is neutralized by a cognate immunity protein, TsiMt. Biochemical assays show that TseMt binds membranes and forms ion‐conducting pores, establishing it as a pore‐forming effector. A 3.0 Å cryo‐electron microscopy structure reveals a distinct three‐domain architecture comprising an N‐terminal MIX‐like domain, a central α‐helical scaffold, and a C‐terminal toxin domain. Genetic analysis and structural modeling indicate that TseMt is delivered through a dedicated PAAR−VgrG−chaperone pathway. Together, these findings define the structural basis, functional mechanism, and delivery pathway of the H4‐T6SS effector TseMt from a clinical P. aeruginosa isolate and reveal its role in mediating bacterial competition.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology and Microbiology School of Life Sciences, Guangming Advanced Research Institute, Southern University of Science and Technology Shenzhen China.
- State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic & Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University Shanghai China.
- Institute of Infectious Diseases, Shenzhen Bay Laboratory Shenzhen China.
- School of Microelectronics, Southern University of Science and Technology Shenzhen China.
- Shenzhen Third People's Hospital, The Second Affiliated Hospital of Southern University of Science and Technology Shenzhen China.
- School of Medicine, Southern University of Science and Technology Shenzhen China.
ORCID-Profile: Tongtong Pei, Liang Yang, Tao Dong
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wu, L., Liu, Y., Huang, R., Zhao, Y., Liu, J., An, Y., Zhang, Y., Wang, X., Zheng, H., Pei, T., Liang, X., Liu, X., Zheng, M., Liu, R., Li, Y., Qu, J., Liu, Y., Yang, L., Zhang, M., & Dong, T. (2026). Functional characterization of a pore‐forming effector TseMt from the H4 type VI secretion system of Pseudomonas aeruginosa. mLife, 5(4), 417-431. https://doi.org/10.1002/mlf2.70108
Vancouver
Wu L, Liu Y, Huang R, Zhao Y, Liu J, An Y, et al. Functional characterization of a pore‐forming effector TseMt from the H4 type VI secretion system of Pseudomonas aeruginosa. mLife. 2026;5(4):417-431. doi:10.1002/mlf2.70108
BibTeX
@article{Wu2026,
author = {Wu, Liwen and Liu, Yong and Huang, Ruolin and Zhao, Ying and Liu, Junbo and An, Ying and Zhang, Yiqiu and Wang, Xingyu and Zheng, Haoyu and Pei, Tongtong and Liang, Xiaoye and Liu, Xiaotian and Zheng, Min and Liu, Ronghui and Li, Yi and Qu, Jiuxin and Liu, Yingxia and Yang, Liang and Zhang, Mingjie and Dong, Tao},
title = {Functional characterization of a pore‐forming effector TseMt from the H4 type VI secretion system of Pseudomonas aeruginosa},
journal = {mLife},
year = {2026},
volume = {5},
number = {4},
pages = {417--431},
doi = {10.1002/mlf2.70108}
}
EUVIMED